BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
Clinical trials for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM trials appear
Sign up with your email to follow new studies for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood cancer transplant study tests safer GVHD prevention
Disease control TerminatedThis phase 2 trial tested two different drug combinations to prevent graft-versus-host disease (GVHD) in 150 people with blood cancers receiving a stem cell transplant from an unrelated donor. Both combinations used cyclosporine and sirolimus, plus either mycophenolate mofetil or…
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Promising combo for tough leukemias hits snag: trial ends early
Disease control TerminatedThis phase II trial tested a combination of two drugs, venetoclax and decitabine, in 235 patients with certain blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) that had come back or not responded to treatment, as well as in older patien…
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New transplant method shows promise for tough blood cancers
Disease control TerminatedThis study tested a bone marrow transplant using a partially matched family donor for people with blood cancers like leukemia. The goal was to see if a milder conditioning regimen and a drug called cyclophosphamide could help patients survive at least 180 days after transplant. T…
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Liver study for cancer drug stopped early – only 2 people joined
Knowledge-focused TerminatedThis study looked at how moderate or severe liver problems change the amount of the cancer drug oral azacitidine in the blood. It was designed for adults with certain blood cancers. The study was stopped early after only 2 people enrolled, so the results are very limited.
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC